• Je něco špatně v tomto záznamu ?

Final overall survival results of a randomized trial comparing bortezomib plus pegylated liposomal doxorubicin with bortezomib alone in patients with relapsed or refractory multiple myeloma

RZ. Orlowski, A. Nagler, P. Sonneveld, J. Bladé, R. Hajek, A. Spencer, T. Robak, A. Dmoszynska, N. Horvath, I. Spicka, HJ. Sutherland, AN. Suvorov, L. Xiu, A. Cakana, T. Parekh, JF. San-Miguel,

. 2016 ; 122 (13) : 2050-6. [pub] 20160518

Jazyk angličtina Země Spojené státy americké

Typ dokumentu klinické zkoušky, fáze III, srovnávací studie, časopisecké články, multicentrická studie, randomizované kontrolované studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc17023976

BACKGROUND: Previous results from an interim analysis of an open-label, randomized, phase 3 study demonstrated that bortezomib combined with pegylated liposomal doxorubicin (PLD) was superior to bortezomib monotherapy in patients with relapsed/refractory multiple myeloma who had previously received one or more lines of therapy. Protocol-defined final survival data from that study are provided here. METHODS: Patients were randomized (1:1) to receive either bortezomib alone (1.3 mg/m(2) intravenously on days 1, 4, 8, and 11 of every 21-day cycle) or bortezomib-PLD (bortezomib plus PLD 30 mg/m(2) intravenously on day 4). The primary endpoint was the time to progression. Secondary efficacy endpoints included overall survival (OS), progression-free survival, and the overall response rate. RESULTS: In total, 646 patients (bortezomib-PLD, n = 324; bortezomib alone, n = 322) were randomized between December, 2004, and March, 2006. On the clinical cutoff date (May 16, 2014) for the final survival analysis, at a median follow-up of 103 months, 79% of patients had died (bortezomib-PLD group: 253 of 324 patients; 78%; bortezomib alone group: 257 of 322 patients; 80%). The median OS in the bortezomib-PLD group was 33 months (95% confidence interval [CI], 28.9-37.1) versus 30.8 months (95% CI, 25.2-36.5) in the bortezomib alone group (hazard ratio, 1.047; 95% CI, 0.879-1.246; P = .6068). Salvage therapies included conventional and novel drugs, which were well balanced between the two treatment groups. CONCLUSIONS: Despite inducing a superior time to progression, long-term follow-up revealed that PLD-bortezomib did not improve OS compared with bortezomib alone in patients with relapsed/refractory multiple myeloma. The inability to sustain the early observed survival advantage may have been caused by the effects of subsequent lines of therapy, and underscores the need for long-term follow-up of phase 3 trials while recognizing the challenge of having adequate power to detect long-term differences in OS. Cancer 2016;122:2050-6. © 2016 American Cancer Society.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17023976
003      
CZ-PrNML
005      
20170829113631.0
007      
ta
008      
170720s2016 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1002/cncr.30026 $2 doi
035    __
$a (PubMed)27191689
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Orlowski, Robert Z $u Department of Lymphoma/Myeloma, The University of Texas, MD Anderson Cancer Center, Houston, Texas.
245    10
$a Final overall survival results of a randomized trial comparing bortezomib plus pegylated liposomal doxorubicin with bortezomib alone in patients with relapsed or refractory multiple myeloma / $c RZ. Orlowski, A. Nagler, P. Sonneveld, J. Bladé, R. Hajek, A. Spencer, T. Robak, A. Dmoszynska, N. Horvath, I. Spicka, HJ. Sutherland, AN. Suvorov, L. Xiu, A. Cakana, T. Parekh, JF. San-Miguel,
520    9_
$a BACKGROUND: Previous results from an interim analysis of an open-label, randomized, phase 3 study demonstrated that bortezomib combined with pegylated liposomal doxorubicin (PLD) was superior to bortezomib monotherapy in patients with relapsed/refractory multiple myeloma who had previously received one or more lines of therapy. Protocol-defined final survival data from that study are provided here. METHODS: Patients were randomized (1:1) to receive either bortezomib alone (1.3 mg/m(2) intravenously on days 1, 4, 8, and 11 of every 21-day cycle) or bortezomib-PLD (bortezomib plus PLD 30 mg/m(2) intravenously on day 4). The primary endpoint was the time to progression. Secondary efficacy endpoints included overall survival (OS), progression-free survival, and the overall response rate. RESULTS: In total, 646 patients (bortezomib-PLD, n = 324; bortezomib alone, n = 322) were randomized between December, 2004, and March, 2006. On the clinical cutoff date (May 16, 2014) for the final survival analysis, at a median follow-up of 103 months, 79% of patients had died (bortezomib-PLD group: 253 of 324 patients; 78%; bortezomib alone group: 257 of 322 patients; 80%). The median OS in the bortezomib-PLD group was 33 months (95% confidence interval [CI], 28.9-37.1) versus 30.8 months (95% CI, 25.2-36.5) in the bortezomib alone group (hazard ratio, 1.047; 95% CI, 0.879-1.246; P = .6068). Salvage therapies included conventional and novel drugs, which were well balanced between the two treatment groups. CONCLUSIONS: Despite inducing a superior time to progression, long-term follow-up revealed that PLD-bortezomib did not improve OS compared with bortezomib alone in patients with relapsed/refractory multiple myeloma. The inability to sustain the early observed survival advantage may have been caused by the effects of subsequent lines of therapy, and underscores the need for long-term follow-up of phase 3 trials while recognizing the challenge of having adequate power to detect long-term differences in OS. Cancer 2016;122:2050-6. © 2016 American Cancer Society.
650    _2
$a intravenózní podání $7 D061605
650    _2
$a protokoly protinádorové kombinované chemoterapie $x aplikace a dávkování $x terapeutické užití $7 D000971
650    _2
$a bortezomib $x aplikace a dávkování $x terapeutické užití $7 D000069286
650    _2
$a přežití bez známek nemoci $7 D018572
650    _2
$a doxorubicin $x aplikace a dávkování $x analogy a deriváty $x terapeutické užití $7 D004317
650    _2
$a rozvrh dávkování léků $7 D004334
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a mnohočetný myelom $x farmakoterapie $x mortalita $7 D009101
650    _2
$a lokální recidiva nádoru $x farmakoterapie $7 D009364
650    _2
$a polyethylenglykoly $x aplikace a dávkování $x terapeutické užití $7 D011092
650    _2
$a výsledek terapie $7 D016896
655    _2
$a klinické zkoušky, fáze III $7 D017428
655    _2
$a srovnávací studie $7 D003160
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a randomizované kontrolované studie $7 D016449
700    1_
$a Nagler, Arnon $u Division of Hematology, Chaim Sheba Medical Center, Tel-Hashomer, Israel.
700    1_
$a Sonneveld, Pieter $u Department of Hematology, Erasmus Medical Center Cancer Institute, Rotterdam, the Netherlands.
700    1_
$a Bladé, Joan $u Department of Clinical Hematology, August Pi I Sunyer Biomedical Research Institute, University of Barcelona, Barcelona, Spain.
700    1_
$a Hajek, Roman $u Department of Hemato-Oncology, University Hospital and Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic.
700    1_
$a Spencer, Andrew $u Malignant Hematology and Stem Cell Transplantation Service, The Alfred Hospital, Melbourne, Australia.
700    1_
$a Robak, Tadeusz $u Department of Hematology, Medical University of Łódź, Łódź, Poland.
700    1_
$a Dmoszynska, Anna $u Hematology and Bone Marrow Transplant Department, Medical University of Lublin, Lublin, Poland.
700    1_
$a Horvath, Noemi $u Department of Hematology, Royal Adelaide Hospital, West Australia, Australia.
700    1_
$a Spicka, Ivan $u Department of Internal Medicine, Charles University General Faculty Hospital, Prague, Czech Republic.
700    1_
$a Sutherland, Heather J $u Division of Hematology, University of British Columbia, Vancouver, British Columbia, Canada.
700    1_
$a Suvorov, Alexander N $u Department of Hematology, First Republican Clinical Hospital of the Ministry of Healthcare of the Udmurt Republic, Izhevsk, Russia.
700    1_
$a Xiu, Liang $u Janssen Research & Development, LLC, Raritan, New Jersey.
700    1_
$a Cakana, Andrew $u Janssen Research & Development, LLC, Raritan, New Jersey.
700    1_
$a Parekh, Trilok $u Janssen Research & Development, LLC, Raritan, New Jersey.
700    1_
$a San-Miguel, Jesús F $u Center for Applied Medical Research, August Pi I Sunyer Biomedical Research Institute, University of Navarra, Pamplona, Spain.
773    0_
$w MED00001031 $t Cancer $x 1097-0142 $g Roč. 122, č. 13 (2016), s. 2050-6
856    41
$u https://pubmed.ncbi.nlm.nih.gov/27191689 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20170720 $b ABA008
991    __
$a 20170829114218 $b ABA008
999    __
$a ok $b bmc $g 1239657 $s 984889
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 122 $c 13 $d 2050-6 $e 20160518 $i 1097-0142 $m Cancer $n Cancer $x MED00001031
LZP    __
$a Pubmed-20170720

Najít záznam

Citační ukazatele

    Možnosti archivace